Julie Perry

No ORCID on file · 4 papers in corpus · active 2023-2025

Study types

  • article 3
  • rct 1

Condition tags

  • endometriosis 3
  • mesh:D004715 1
  • dysmenorrhea 1
  • adenomyosis 1
  • dyspareunia 1
  • mesh:D004412 1
  • mesh:D017699 1
article 2025
Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2
Fertility and sterility ·doi:10.1016/j.fertnstert.2025.04.037

OBJECTIVE: To assess the effects of relugolix combination therapy in women with uterine fibroids (UFs) and concomitant ultrasound-diagnosed adenomyosis. DESIGN: This post hoc analysis used pooled data from completers of the pivotal LIBERTY …

rct 2024
Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.06.009

OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate) for up to 2 years in the SPIRIT long-term extension study on functioning and health-relate…

article 2023
Bleeding Patterns With Relugolix Combination Therapy in Women With Endometriosis-Associated Pain [ID: 1345374]
·doi:10.1097/01.aog.0000929844.43483.20

INTRODUCTION: Relugolix combination therapy (Relugolix-CT: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) significantly improved endometriosis-associated pain versus placebo in the SPIRIT 1&2 studies. Efficacy was maintained…

article 2023
BONE MINERAL DENSITY AFTER TWO YEARS OF TREATMENT WITH RELUGOLIX COMBINATION THERAPY AND ONE-YEAR POST-TREATMENT FOLLOW-UP IN WOMEN WITH ENDOMETRIOSIS: SPIRIT PROGRAM
·doi:10.1016/j.fertnstert.2023.08.234